These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 677859)

  • 1. Surveillance of gentamicin-resistant gram-negative bacilli in a general hospital.
    Kauffman CA; Ramundo NC; Williams SG; Dey CR; Phair JP; Watanakunakorn C
    Antimicrob Agents Chemother; 1978 Jun; 13(6):918-23. PubMed ID: 677859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of gentamicin and/or tobramycin resistant gram-negative bacilli to seven aminoglycosides.
    Watanakunakorn C; Kauffman CA
    Infection; 1978; 6(3):111-5. PubMed ID: 98451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to gentamicin and amikacin of gram-negative organisms isolated from horses.
    Orsini JA; Benson CE; Spencer PA; Van Miller E
    Am J Vet Res; 1989 Jun; 50(6):923-5. PubMed ID: 2669575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endemic aminoglycoside resistance in gram-negative bacilli: epidemiology and mechanisms.
    Weinstein RA; Nathan C; Gruensfelder R; Kabins SA
    J Infect Dis; 1980 Mar; 141(3):338-45. PubMed ID: 6767795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to gentamicin: a growing concern.
    Siebert WT; Moreland NJ; Williams TW
    South Med J; 1977 Mar; 70(3):289-92. PubMed ID: 322294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of infections caused by gentamicin-resistant enterobacteriaceae and Pseudomonas aeruginosa over 15 years at the Nashville Veterans Administration Medical Center.
    Alford RH; Hall A
    Rev Infect Dis; 1987; 9(6):1079-86. PubMed ID: 3321357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms.
    Tally FP; Louie TJ; Weinstein WM; Bartlett JG; Gorbach SL
    Ann Intern Med; 1975 Oct; 83(4):484-8. PubMed ID: 1101761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal analysis of endemic gentamicin- and tobramycin-resistant gram-negative bacilli in a community hospital.
    Magnussen CR; Jacobson MT
    Infect Control; 1984 Feb; 5(2):88-92. PubMed ID: 6559770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of gentamicin-resistant, gram-negative bacillary colonization in a spinal cord injury unit.
    Shlaes DM; Currie CA; Rotter G; Eanes M; Floyd R
    J Clin Microbiol; 1983 Aug; 18(2):227-35. PubMed ID: 6619279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center.
    Gerding DN; Larson TA
    Am J Med; 1985 Jul; 79(1A):1-7. PubMed ID: 4025364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gentamicin-resistant Pseudomonas aeruginosa and Serratia marcescens in a general hospital.
    Meyer RD; Lewis RP; Halter J; White M
    Lancet; 1976 Mar; 1(7959):580-3. PubMed ID: 55850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R factors in gentamicin-resistant organisms causing hospital infection.
    Richmond AS; Simberkoff MS; Rahal JJ; Schaefler S
    Lancet; 1975 Dec; 2(7946):1176-8. PubMed ID: 53660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
    Saavedra S; Vera D; Ramírez-Ronda CH
    Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tobramycin, amikacin, sissomicin, and gentamicin resistant Gram-negative rods.
    Drasar FA; Farrell W; Maskell J; Williams JD
    Br Med J; 1976 Nov; 2(6047):1284-7. PubMed ID: 1000196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections.
    Tsai TY; Chang SC; Hsueh PR; Feng NH; Wang JT
    J Microbiol Immunol Infect; 2007 Dec; 40(6):481-6. PubMed ID: 18087627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the in vitro activities of BB-K8 and three other aminoglycosides against 215 strains of Pseudomonas and Enterobacteriaceae with variable sensitivity to kanamycin and gentamicin.
    Yourassowsky E; Schoutens E; Vanderlinden MP
    Chemotherapy; 1975; 21(1):45-51. PubMed ID: 807457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year surveillance of aminoglycoside usage in a university hospital.
    Betts RF; Valenti WM; Chapman SW; Chonmaitree T; Mowrer G; Pincus P; Messner M; Robertson R
    Ann Intern Med; 1984 Feb; 100(2):219-22. PubMed ID: 6691664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of gentamicin resistance in nosocomial infections.
    John JF; Rubens CE; Farrar WE
    Am J Med Sci; 1980; 279(1):25-30. PubMed ID: 6768292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and microbiologic consequences of amikacin use during a 42-month period.
    Berk SL; Alvarez S; Ortega G; Verghese A; Holtsclaw-Berk SA
    Arch Intern Med; 1986 Mar; 146(3):538-41. PubMed ID: 3954526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of gentamicin-resistant bacteria: experience with tobramycin therapy of infections due to gentamicin-resistant organisms.
    Moellering RC; Wennersten C; Kunz LJ
    J Infect Dis; 1976 Aug; 134 Suppl():S40-9. PubMed ID: 972284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.